A Phase 2 interventional study of LY2157299 and Sorafenib in Hepatocellular Carcinoma, sponsored by Eli Lilly and Company. Completed at 16 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-25.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing sorafenib in Carcinoma, Hepatocellular — 5 open to participants now, 7 under way, 1 of them phase 3. Sorafenib · Carcinoma, Hepatocellular.
Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, this one is the 25th largest by enrollment, is one of 8 that started in 2014, is one of 44 in phase 2, and was the 78th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →5 of the 104 studies testing sorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–99
Zhejiang Haichang Biotech Co., Ltd. · Sites in China, Hong Kong
Ages 18+
Assiut University · Sites in Egypt
Ages 18–80
St. Jude Children's Research Hospital · Sites in United States
Ages up to 30
Humanity & Health Medical Group Limited · Sites in Hong Kong
Ages 18+
By country, each count listing its studies:
Sorafenib: first FDA approval 2005 (NEXAVAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 59 · Phase 3 17 · Phase 4 3
First in 2002; this study’s year is marked. 8 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 44 across the 104 interventional studies. Of the 71 that completed or were terminated, 24 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 4 in phase 2, and was the 7th registered.
Eli Lilly and Company’s Carcinoma, Hepatocellular studies by the year they started, since 2008.
4 of the studies testing sorafenib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT06309485Zhejiang Haichang Biotech Co., Ltd.Phase 2 Study of WGI-0301 for Advanced HCC | 2026-12 |
| NCT05669339University of FloridaAD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | 2027-04 |
| NCT01840592Memorial Sloan Kettering Cancer CenterSorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, from their registry updates:
Among Eli Lilly and Company’s 13 in Carcinoma, Hepatocellular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2157299 in participants with hepatocellular carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
150 mg galunisertib administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 days cycle).
Drug: LY2157299
150 mg galunisertib administered orally, BID for 14 days followed by 14 days with no study drug (28 days cycle). 400 mg sorafenib administered orally BID for 28 days.
Drug: LY2157299 · Drug: Sorafenib
Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 days cycle). 400 mg sorafenib administered orally BID for 28 days.
Drug: Sorafenib · Drug: Placebo
Overall Survival (OS): Number of Events
OS defined as the time from the date of randomization to the date of death due to any cause. An overall survival event was defined as death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive. The number of participants with overall survival events (deaths) is reported.
Time frame: Randomization to Date of Death from Any Cause (Up To 24 Months)
Population Pharmacokinetics (PopPK): Mean Population Clearance of Galunisertib
Population mean (between-subject coefficient variance \[CV %\]) apparent clearance.
Time frame: Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1
Population Pharmacokinetics (PopPK): Steady State Apparent Volume of Distribution (Vss) of Galunisertib
Population Vss \[distribution of galunisertib in the body at steady state\] after a single dose of galunisertib.
Time frame: Cycle (C) 1: Day (D)1: Predose, 0.5-2 hours(h) Postdose; D14: Predose, 0.5-2, 3-5 h, Postdose; D15 Morning; D22 Morning; Predose C2 and C3 Predose D1
Time to Tumor Progression (TTP)
TTP at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. Progression was assessed by the Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.Progressive Disease (PD)is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Randomization to the Date of Objective Progressive Disease or Date of Death due to Study Disease, whichever came first (Up To 24 Months)
Progression-Free Survival (PFS)
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
Time frame: Randomization to Measured Progressive Disease or Death (Up To 24 Months)
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
Time frame: Randomization to Measured Progressive Disease (Up To 24 Months)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Score
EORTC QLQ-C30 consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much). 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.
Time frame: Baseline, 24 Months
Change From Baseline in EORTC QLQ Hepatocellular Carcinoma (HCC-18) Questionnaire Score
The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as abdominal swelling, sex life, fatigue, body image, jaundice, nutrition, pain and fever. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a symptom scale/item represented a high level of symptomatology/problem.
Time frame: Baseline, 24 Months
| Milestone | 150 Milligram (mg) Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy |
|---|---|---|---|
| Started | 20 | 74 | 38 |
| Received at least 1 dose of study drug | 20 | 74 | 38 |
| Completed | 19 | 72 | 36 |
| Not completed | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
OS defined as the time from the date of randomization to the date of death due to any cause. An overall survival event was defined as death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive. The number of participants with overall survival events (deaths) is reported.
| Participants with events | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy |
|---|---|---|---|
| Overall Survival (OS): Number of Events | 15 | 58 | 31 |
Population mean (between-subject coefficient variance \[CV %\]) apparent clearance.
| Liter per hour (L/hr) | Galunisertib Monotherapy and Galunisertib + Sorafenib Therapy |
|---|---|
| Population Pharmacokinetics (PopPK): Mean Population Clearance of Galunisertib | 33.6 ± 48 |
Population Vss \[distribution of galunisertib in the body at steady state\] after a single dose of galunisertib.
| Liters (L) | Galunisertib Monotherapy and Galunisertib + Sorafenib Therapy |
|---|---|
| Population Pharmacokinetics (PopPK): Steady State Apparent Volume of Distribution (Vss) of Galunisertib | 192 ± 69 |
TTP at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. Progression was assessed by the Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.Progressive Disease (PD)is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| Months | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy |
|---|---|---|---|
| Time to Tumor Progression (TTP) | 1.41 (1.38 to 2.76) | 2.86 (2.63 to 4.21) | 4.14 (2.76 to 8.21) |
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
| Months | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy |
|---|---|---|---|
| Progression-Free Survival (PFS) | 1.41 (1.38 to 2.76) | 2.86 (2.63 to 4.07) | 4.14 (2.76 to 5.59) |
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
| Percentage of participants | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy |
|---|---|---|---|
| Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | 0.05 (0.001 to 0.249) | 0.027 (0.003 to 0.094) | 0.158 (0.060 to 0.313) |
EORTC QLQ-C30 consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much). 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.
| units on a scale | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy |
|---|---|---|---|
| Global health status | 43.42 ± 23.171 | 55.90 ± 22.473 | 58.57 ± 17.326 |
| Functional scale: Physical functioning | 84.56 ± 16.338 | 82.87 ± 19.613 | 80.95 ± 16.580 |
| Functional scale: Role functioning | 89.47 ± 14.918 | 82.05 ± 24.880 | 85.24 ± 19.289 |
| Functional Scale: Emotional Functioning | 84.65 ± 18.271 | 87.18 ± 17.247 | 86.90 ± 13.898 |
| Functional Scale: Cognitive Functioning | 89.47 ± 16.860 | 91.03 ± 14.754 | 85.71 ± 18.142 |
| Functional Scale: Social Functioning | 83.33 ± 24.845 | 84.10 ± 19.859 | 84.29 ± 18.052 |
| Symptom Scale: Fatigue | 21.05 ± 23.393 | 24.10 ± 22.444 | 25.40 ± 18.390 |
| Symptom Scale: Nausea and Vomiting | 2.63 ± 8.358 | 3.85 ± 8.725 | 3.33 ± 8.856 |
| Symptom scale: Pain | 17.54 ± 19.621 | 17.18 ± 25.340 | 14.76 ± 20.521 |
| Symptom scale: Dyspnoea | 17.54 ± 28.040 | 11.79 ± 19.922 | 12.38 ± 18.232 |
| Symptom scale: Insomnia | 21.05 ± 31.838 | 9.74 ± 19.296 | 16.19 ± 16.903 |
| Symptom scale: Appetite loss | 15.79 ± 25.744 | 16.92 ± 25.768 | 18.10 ± 23.351 |
| Symptom scale: Constipation | 5.26 ± 12.488 | 6.15 ± 13.033 | 6.67 ± 15.760 |
| Symptom scale: Diarrhoea | 10.53 ± 19.413 | 4.62 ± 13.013 | 10.48 ± 17.660 |
| Symptom scale: Financial difficulties | 15.79 ± 25.744 | 23.08 ± 26.954 | 20.95 ± 22.989 |
The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as abdominal swelling, sex life, fatigue, body image, jaundice, nutrition, pain and fever. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a symptom scale/item represented a high level of symptomatology/problem.
| units on a scale | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy |
|---|---|---|---|
| Abdominal swelling | 24.56 ± 33.040 | 32.82 ± 31.453 | 27.62 ± 24.899 |
| Sex Life | 28.07 ± 31.940 | 58.97 ± 35.242 | 46.08 ± 35.783 |
| Fatigue | 32.16 ± 21.563 | 47.86 ± 29.128 | 46.98 ± 26.278 |
| Body Image | 28.07 ± 26.089 | 36.15 ± 22.930 | 31.90 ± 20.758 |
| Jaundice | 20.18 ± 25.202 | 27.69 ± 25.392 | 25.24 ± 21.531 |
| Nutrition | 22.46 ± 21.223 | 34.05 ± 23.456 | 34.48 ± 18.611 |
| Pain | 25.44 ± 18.732 | 25.38 ± 21.471 | 30.95 ± 21.822 |
| Fever | 14.04 ± 16.909 | 25.38 ± 25.019 | 20.48 ± 20.646 |
Collected over Up To 63 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 150 mg Galunisertib Monotherapy | 15/20 (75%) | 6/20 (30%) | 17/20 (85%) |
| 150 mg Galunisertib + 400 mg Sorafenib Therapy | 58/74 (78.4%) | 31/74 (41.9%) | 73/74 (98.6%) |
| 400 mg Sorafenib + Placebo Therapy | 31/38 (81.6%) | 11/38 (28.9%) | 38/38 (100%) |
| Event | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy |
|---|---|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/20 | 4/74 | 0/38 |
| PyrexiaGeneral disorders | 0/20 | 4/74 | 0/38 |
| Abdominal painGastrointestinal disorders | 0/20 | 3/74 | 2/38 |
| Hearing impairedEar and labyrinth disorders | 1/20 | 0/74 | 0/38 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/20 | 0/74 | 0/38 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/20 | 3/74 | 0/38 |
| JaundiceHepatobiliary disorders | 1/20 | 0/74 | 0/38 |
| PneumoniaInfections and infestations | 1/20 | 1/74 | 1/38 |
| SepsisInfections and infestations | 1/20 | 0/74 | 0/38 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/20 | 0/74 | 0/38 |
| Event | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/20 | 29/74 | 22/38 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 4/20 | 42/74 | 19/38 |
| HypophosphataemiaMetabolism and nutrition disorders | 2/20 | 33/74 | 13/38 |
| Alanine aminotransferase increasedInvestigations | 2/20 | 23/74 | 15/38 |
| Aspartate aminotransferase increasedInvestigations | 2/20 | 26/74 | 15/38 |
| Blood bilirubin increasedInvestigations | 2/20 | 11/74 | 15/38 |
| FatigueGeneral disorders | 6/20 | 23/74 | 14/38 |
| Decreased appetiteMetabolism and nutrition disorders | 3/20 | 27/74 | 12/38 |
| PyrexiaGeneral disorders | 1/20 | 26/74 | 5/38 |
| Platelet count decreasedInvestigations | 0/20 | 19/74 | 13/38 |
All randomized participants.
| Age, Categorical(Participants) | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 55 | 28 | 96 |
| >=65 years | 7 | 19 | 10 | 36 |
| Age, Continuous(years) | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy | Total |
|---|---|---|---|---|
| Mean | 60.6 ± 7.8 | 59.0 ± 8.5 | 58.6 ± 11.8 | 59.1 ± 9.4 |
| Sex: Female, Male(Participants) | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy | Total |
|---|---|---|---|---|
| Female | 4 | 12 | 1 | 17 |
| Male | 16 | 62 | 37 | 115 |
| Race (NIH/OMB)(Participants) | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 20 | 74 | 38 | 132 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy | Total |
|---|---|---|---|---|
| South Korea | 7 | 33 | 13 | 53 |
| Hong Kong | 6 | 10 | 6 | 22 |
| China | 0 | 15 | 8 | 23 |
| Taiwan | 7 | 11 | 9 | 27 |
| Thailand | 0 | 5 | 2 | 7 |
| Weight(kilogram (kg)) | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy | Total |
|---|---|---|---|---|
| Median | 66.400 (40.00 to 83.20) | 63.575 (39.70 to 87.00) | 62.400 (51.10 to 82.15) | 63.575 (39.70 to 87.00) |
| Height(Centimeter (cm)) | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy | Total |
|---|---|---|---|---|
| Mean | 162.84 ± 7.38 | 165.30 ± 7.50 | 166.55 ± 5.69 | 165.29 ± 7.05 |
| BMI(kilogram per square metre (kg/m2)) | 150 mg Galunisertib Monotherapy | 150 mg Galunisertib + 400 mg Sorafenib Therapy | 400 mg Sorafenib + Placebo Therapy | Total |
|---|---|---|---|---|
| Mean | 24.806 ± 4.105 | 23.224 ± 3.248 | 22.843 ± 3.062 | 23.354 ± 3.373 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Aug 2014 to primary completion in Jun 2017, 34 months.
Results were first posted in Dec 2020, 3 years 5 months after primary completion. A results delay was requested in Jun 2018.
Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 34 months is below that.
Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: LY-2157299 · Sorafenib